Astellas starts dosing gilteritinib patients in Phase III trial to treat AML

Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news